Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Palbociclib

FDA-approved product (capsule, oral), marketed as Ibrance, Palbociclib.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Palbociclib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • HER2 Positive Breast Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Cyclin-dependent kinase (cdk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Palbociclib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Palbociclib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

    NCT05384119 · start 2023-01-09

    Registered record
    Registry ID
    NCT05384119
    Conditions
    Breast Cancer
    Interventions
    TTI-101; Palbociclib; Aromatase inhibitor (AI); fulvestrant; ribociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2023-01-09
    Completion
    2024-04-25
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionTTI-101; Palbociclib; Aromatase inhibitor (AI); fulvestrant +1 more
    PhasePhase 1
    Registry statusTerminated

  • Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

    NCT04966481 · start 2022-04-06

    Registered record
    Registry ID
    NCT04966481
    Conditions
    HPV-unrelated Head and Neck Squamous Cell Carcinoma
    Interventions
    Palbociclib; Cetuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-04-06
    Completion
    2028-02-28
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHPV-unrelated Head and Neck Squamous Cell Carcinoma
    InterventionPalbociclib; Cetuximab
    PhasePhase 3
    Registry statusRecruiting

  • European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies

    NCT05043506 · start 2022-02-08

    Registered record
    Registry ID
    NCT05043506
    Conditions
    Metastatic Breast Cancer
    Interventions
    Palbociclib + aromatase inhibitor; Aromatase inhibitor
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-02-08
    Completion
    2023-11-02
    Enrolment
    1,939

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionPalbociclib + aromatase inhibitor; Aromatase inhibitor
    PhaseNot recorded
    Registry statusCompleted

  • Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study

    NCT05067530 · start 2022-01-01

    Registered record
    Registry ID
    NCT05067530
    Conditions
    Triple Negative Breast Neoplasms
    Interventions
    Palbociclib; Paclitaxel; Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2022-01-01
    Completion
    2026-12-06
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Neoplasms
    InterventionPalbociclib; Paclitaxel; Carboplatin
    PhasePhase 2
    Registry statusNot yet recruiting

  • Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

    NCT05969184 · start 2021-12-12

    Registered record
    Registry ID
    NCT05969184
    Conditions
    Breast Neoplasm Female
    Interventions
    CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-12-12
    Completion
    2026-06-25
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasm Female
    InterventionCDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
    PhasePhase 2
    Registry statusCompleted

  • Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

    NCT05343117 · start 2021-12-01

    Registered record
    Registry ID
    NCT05343117
    Conditions
    Hormone Receptor Positive Advanced Breast Cancer
    Interventions
    Palbociclib based-therapy as initial endocrine therapy; Palbociclib based-therapy after chemotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-12-01
    Completion
    2024-06-01
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHormone Receptor Positive Advanced Breast Cancer
    InterventionPalbociclib based-therapy as initial endocrine therapy; Palbociclib based-therapy after chemotherapy
    PhaseNot recorded
    Registry statusUnknown

  • Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

    NCT04916509 · start 2021-09-13

    Registered record
    Registry ID
    NCT04916509
    Conditions
    Breast Neoplasms
    Interventions
    Palbociclib plus an aromatase inhibitor; Palbociclib plus fulvestrant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-09-13
    Completion
    2022-12-27
    Enrolment
    258

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms
    InterventionPalbociclib plus an aromatase inhibitor; Palbociclib plus fulvestrant
    PhaseNot recorded
    Registry statusCompleted

  • Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

    NCT04996160 · start 2021-07-09

    Registered record
    Registry ID
    NCT04996160
    Conditions
    Acute Lymphoblastic Leukemia, Pediatric; Relapsed Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia
    Interventions
    Palbociclib; Dexamethasone; Bortezomib; Doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-07-09
    Completion
    2023-10-16
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia, Pediatric; Relapsed Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia
    InterventionPalbociclib; Dexamethasone; Bortezomib; Doxorubicin
    PhasePhase 1
    Registry statusCompleted

  • Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

    NCT04653740 · start 2020-09-08

    Registered record
    Registry ID
    NCT04653740
    Conditions
    Advanced Breast Cancer
    Interventions
    specimen sample collection
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2020-09-08
    Completion
    2027-11
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    Interventionspecimen sample collection
    PhaseNot applicable
    Registry statusActive not recruiting

  • A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

    NCT04436744 · start 2020-09-04

    Registered record
    Registry ID
    NCT04436744
    Conditions
    Early Breast Cancer
    Interventions
    Giredestrant; Anastrozole; Palbociclib; Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-09-04
    Completion
    2021-11-24
    Enrolment
    221

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly Breast Cancer
    InterventionGiredestrant; Anastrozole; Palbociclib; Surgery
    PhasePhase 2
    Registry statusCompleted

  • A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

    NCT04224272 · start 2020-06-10

    Registered record
    Registry ID
    NCT04224272
    Conditions
    HER2+/HR+ Breast Cancer
    Interventions
    ZW25 (Zanidatamab); Palbociclib; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-06-10
    Completion
    2025-06-30
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2+/HR+ Breast Cancer
    InterventionZW25 (Zanidatamab); Palbociclib; Fulvestrant
    PhasePhase 2
    Registry statusCompleted

  • Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE

    NCT04720768 · start 2020-06-04

    Registered record
    Registry ID
    NCT04720768
    Conditions
    Melanoma; Metastasis
    Interventions
    Binimetinib; Encorafenib; Palbociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2020-06-04
    Completion
    2024-12-04
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma; Metastasis
    InterventionBinimetinib; Encorafenib; Palbociclib
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

    NCT03936270 · start 2020-03-05

    Registered record
    Registry ID
    NCT03936270
    Conditions
    Ovarian Cancer
    Interventions
    Palbociclib 125mg; Letrozole 2.5mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-03-05
    Completion
    2023-05-02
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionPalbociclib 125mg; Letrozole 2.5mg
    PhasePhase 2
    Registry statusCompleted

  • CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer

    NCT04220476 · start 2020-03-04

    Registered record
    Registry ID
    NCT04220476
    Conditions
    Breast Cancer
    Interventions
    Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions); Letrozole 2.5Mg Tab; Palbociclib 125mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2020-03-04
    Completion
    2028-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionStereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions); Letrozole 2.5Mg Tab; Palbociclib 125mg
    PhasePhase 2
    Registry statusWithdrawn

  • Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

    NCT04526028 · start 2019-09-13

    Registered record
    Registry ID
    NCT04526028
    Conditions
    Breast Cancer; Fulvestrant; Palbociclib
    Interventions
    Fulvestrant Injectable Product; Palbociclib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-09-13
    Completion
    2023-05-31
    Enrolment
    612

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Fulvestrant; Palbociclib
    InterventionFulvestrant Injectable Product; Palbociclib
    PhaseNot recorded
    Registry statusUnknown